Prelude Therapeutics annual free cash flow per share
2019
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Free Cash Flow Per Share Growth & History (PRLD)
Prelude Therapeutics's free cash flow per share was -$0.73 for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$0.73 | $0.63 | — |
| 2024 | 2024-12-31 | -$1.37 | $0.46 | — |
| 2023 | 2023-12-31 | -$1.83 | -$0.00 | — |
| 2022 | 2022-12-31 | -$1.83 | $0.03 | — |
| 2021 | 2021-12-31 | -$1.86 | $1.89 | — |
| 2020 | 2020-12-31 | -$3.75 | $12.10 | — |
| 2019 | 2019-12-31 | -$15.85 | — | — |
Prelude Therapeutics quarterly free cash flow per share
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$0.16 | $0.19 | — |
| Q1 2026 | 2026-03-31 | -$0.26 | $0.19 | — |
| Q3 2025 | 2025-09-30 | -$0.25 | $0.11 | — |
| Q2 2025 | 2025-06-30 | -$0.34 | -$0.03 | — |
| Q1 2025 | 2025-03-31 | -$0.45 | -$0.03 | — |
| Q3 2024 | 2024-09-30 | -$0.36 | $0.03 | — |
| Q2 2024 | 2024-06-30 | -$0.31 | $0.20 | — |
| Q1 2024 | 2024-03-31 | -$0.42 | $0.22 | — |
| Q3 2023 | 2023-09-30 | -$0.39 | $0.06 | — |
| Q2 2023 | 2023-06-30 | -$0.51 | -$0.10 | — |
| Q1 2023 | 2023-03-31 | -$0.65 | -$0.16 | — |
| Q3 2022 | 2022-09-30 | -$0.45 | $0.03 | — |
| Q2 2022 | 2022-06-30 | -$0.41 | $0.03 | — |
| Q1 2022 | 2022-03-31 | -$0.49 | -$0.11 | — |
| Q3 2021 | 2021-09-30 | -$0.48 | $3.48 | — |
| Q2 2021 | 2021-06-30 | -$0.44 | $3.87 | — |
| Q1 2021 | 2021-03-31 | -$0.38 | $5.01 | — |
| Q3 2020 | 2020-09-30 | -$3.97 | — | — |
| Q2 2020 | 2020-06-30 | -$4.31 | — | — |
| Q1 2020 | 2020-03-31 | -$5.39 | — | — |
Prelude Therapeutics free cash flow per share trends
Over the last five fiscal years, Prelude Therapeutics's free cash flow per share increased from -$3.75 to -$0.73, a change of $3.02. The latest reported quarter, Q2 2026, shows -$0.16.
About the metric
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
Calculation and source
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...